As of Feb 21, 2025, Apple Relative Value is $95.6. This suggests it may be overvalued by 61.9% compared to its current price of around $250.6.
As of Feb 21, 2025, Alnylam Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $250.6, using a discount rate of 7.4% and terminal growth rate of 3.0%.
As of Feb 21, 2025, Apple Intrinsic Value is $95.4. This suggests it may be overvalued by 61.9% compared to its current price of around $250.6.